Tirzepatide: The Next Diabetes Treatment?
hosted byConnect Educate Impact (CEI)Tirzepatide: The Next Diabetes Treatment? is organized by Connect Educate Impact (CEI).
Initial Release Date: April 13, 2022
Planned Expiration Date: April 13, 2025
Description:
Tirzepatide is a novel drug that works as an agonist of both GLP-1 and GIP. How does this compare to semaglutide, a GLP-1 agonist? Join us as we discuss the SURPASS-2 trial, and compare the drugs' mechanisms of action, effect on hemoglobin A1c, impact on weight, and overall clinical outcomes.
Objectives:
Upon successful completion of this application-based course, pharmacists and pharmacy students should be able to:
• Describe the mechanism of action of tripeptide
• Compare and contrast tirzepatide with semaglutide
• Discuss clinical trial data on tirzepatide's effect on hemoglobin A1c at various doses as compared to semaglutide
• Discuss the impact of tripeptide on patient weight
• Develop a conclusion for tirzepatide's role in patient-centered diabetes care based on a clinical trial
